[go: up one dir, main page]

UA94021C2 - Modified antagonists (muteins) of receptor il-4 - Google Patents

Modified antagonists (muteins) of receptor il-4

Info

Publication number
UA94021C2
UA94021C2 UAA200603391A UAA200603391A UA94021C2 UA 94021 C2 UA94021 C2 UA 94021C2 UA A200603391 A UAA200603391 A UA A200603391A UA A200603391 A UAA200603391 A UA A200603391A UA 94021 C2 UA94021 C2 UA 94021C2
Authority
UA
Ukraine
Prior art keywords
antagonist
receptor
relates
modified
mentioned
Prior art date
Application number
UAA200603391A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Кларк Пен
Стив Рожняк
Джери Майкл Грев
Стефани Л. Юнг
Малинда Лонгфре
Тереза Мо-фан Вонг
Адриан Томкинсон
Original Assignee
Байер Фармасьютикелз Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Фармасьютикелз Корпорейшн filed Critical Байер Фармасьютикелз Корпорейшн
Publication of UA94021C2 publication Critical patent/UA94021C2/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

An invention relates to the modified antagonist (muteine) of receptor IL-4 (IL-4R). The invention also relates to the mentioned antagonist, connected with polymer of nonprotein nature in amino acid residue in the position of 104 IL-4, where the mentioned polymer represents polyethylene glycol, polypropylene glycol or alkylene oxide polymer. The invention also relates to the polynucleotide, coding mentioned antagonist, to the method for preparation of antagonist, pharmaceutical composition, containing it, and to using of modified antagonist for healing of disorders in human, connected with increased activity of IL-4 and IL-13.
UAA200603391A 2003-08-29 2004-07-20 Modified antagonists (muteins) of receptor il-4 UA94021C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49890603P 2003-08-29 2003-08-29

Publications (1)

Publication Number Publication Date
UA94021C2 true UA94021C2 (en) 2011-04-11

Family

ID=37444459

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200603391A UA94021C2 (en) 2003-08-29 2004-07-20 Modified antagonists (muteins) of receptor il-4

Country Status (3)

Country Link
CN (1) CN100549030C (en)
UA (1) UA94021C2 (en)
ZA (1) ZA200601759B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111378026A (en) * 2018-12-27 2020-07-07 天津键凯科技有限公司 Method for preparing PEG (polyethylene glycol) biological molecules with controllable binding sites

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4423131A1 (en) * 1994-07-01 1996-01-04 Bayer Ag New hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4
US5986059A (en) * 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists

Also Published As

Publication number Publication date
ZA200601759B (en) 2007-04-25
CN100549030C (en) 2009-10-14
CN1871254A (en) 2006-11-29

Similar Documents

Publication Publication Date Title
EP1607100A4 (en) CURATIVE TREATMENT FOR MEDICAL INJURIES CONTAINING AN INTERLEUKIN-6 ANTAGONIST
BR0008688A (en) Recombinant il-18 antagonists usable in the treatment of il-18 mediated disorders
DE60335891D1 (en) SULPHONYLAMINE ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONIST
WO2004019884A3 (en) Agents and methods for enhancing bone formation
HUP0303651A3 (en) N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor and pharmaceutical compositions containing them
CY1113145T1 (en) Molecular Recipients of Thymic Stratified Lymphopoietin and Their Uses
IS6750A (en) Synchronous heterocyclic succinimide compounds and their analogues, configured for nuclear hormone receptor activity
WO2003053358A3 (en) Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
DE60313004D1 (en) ALPHA-7 NICOTIC ACID RECEPTOR AGONISTS AND STATINE IN COMBINATION
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
WO2004074486A3 (en) Fusion proteins of interferon alpha muteins with improved properties
UA91820C2 (en) Therapeutic uses of chemokine variants
IL168836A (en) Pyrimidine-sulfamides and their use as endothelin receptor antagonist
UA94021C2 (en) Modified antagonists (muteins) of receptor il-4
WO2008049098A3 (en) ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR α1
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
AU1454502A (en) Ige receptor antagonists
EP2301625A3 (en) Compositions and methods for treating cognitive disorders
HUP0401858A3 (en) Gal3 receptor antagonist pyrimidine and indolone-derivatives and their use for preparation of pharmaceutical compositions suitable for the treatment of depression and/or anxiety
HUP9801835A3 (en) Bicyclic tachykinins antagonists, preparation thereof and their use in pharmaceutical composition
WO2006060346A3 (en) 8-phenyl-5,6,7,8-hydroquinoline tachykinin receptor antagonists
WO2002069944A3 (en) Novel medicament compositions based on anticholinergics and on nk1 receptor antagonists
AU2003231019A8 (en) Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use
WO2002007676A3 (en) Compounds having affinity for the granulocyte-colony stimulating factor receptor (g-csfr)
ATE364399T1 (en) A COMPOSITION CONTAINING A CNS-PENETRATING NK-1 RECEPTOR ANTAGONIST AND AN ANXIOLOGIANT OR ANTIDEPRESSANT AGENT FOR THE TREATMENT OF DEPRESSION AND ANXIETY